Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy ...

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy ...

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European ...

Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.

The Dow, S&P 500, and Nasdaq rose Thursday as the stock market digested data on retail sales and jobless claims.

Rockets star Kevin Durant could've been traded to the Minnesota Timberwolves but reportedly rejected the mega deal to instead end up in Houston.

Volvo CEO Hakan Samuelsson on Thursday urged the European Union to slash its auto tariffs on the US in an attempt to sway President Trump to lower his own hefty duties on foreign vehicles.

Shares of Sarepta Therapeutics SRPT surged more than 30% in after-market trading yesterday after the company announced a strategic restructuring plan focused on pipeline reprioritization and ...

Sarepta's stock is jumping Thursday morning after the company announced a restructuring plan. Thomas Fuller / SOPA Images / LightRocket via Getty Images ...